moxifloxacin + amoxicillin + omeprazole

This is a combination of three pharmaceutical agents: - **Moxifloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. - **Amoxicillin** is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. - **Omeprazole** is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. This combination does not correspond to any widely recognized or marketed fixed-dose product but may be used off-label in clinical practice as an alternative triple therapy regimen for the eradication of *Helicobacter pylori* infection. Standard triple therapy typically uses clarithromycin instead of moxifloxacin; however, moxifloxacin-based regimens have been studied as alternatives in cases where resistance or intolerance to standard antibiotics exists[1][8]. The rationale for this combination is to combine two antibiotics with different mechanisms (moxifloxacin and amoxicillin) with acid suppression (omeprazole), which enhances antibiotic efficacy against *H. pylori*.